Consolidation therapy for newly diagnosed pediatric high-risk neuroblastoma patients using busulfan/melphalan, autologous hematopoietic cell transplant, anti-GD2 antibody, GM-CSF, IL-2 and haploidentical NK cells

Podobne knjige/članki

• Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
  od: Yu, Alice L., et al.
  Izdano: (2010)
• Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution
  od: Mamcarz, Ewelina, et al.
  Izdano: (2019)
• Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial
  od: Nguyen, Rosa, et al.
  Izdano: (2020)
• G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
  od: Martinez Sanz, Paula, et al.
  Izdano: (2021)
• Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database
  od: Desai, Ami V., et al.
  Izdano: (2016)